このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy (ABODE NAC)

2026年11月15日 更新者:University Health Network, Toronto

At-home Breast Oncology Care Delivered With E-health Solutions - The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy

Over 12,000 women in Ontario will be diagnosed with BC this year. The COVID-19 pandemic changed the healthcare system, making it important to have high-quality virtual (online) care. Mobile health, which means getting health services on your phone, has become a common part of healthcare.

A previously developed app will be used in this study to improve the virtual care experience for BC patients that will be undergoing neoadjuvant chemotherapy. With this app, patients can:

  • Get personalized resources that can help them navigate through the stages of their treatment.
  • Access vetted information about their cancer & treatment from a health library.
  • Receive surveys about their health and well-being.
  • Get mental and social support from an e-coach, who are volunteers trained to help and support patients. The e-coaches will provide information, listen to how participants are feeling, and help participants find information they might need.
  • Connect with a physiotherapist to discuss healthy living and wellness.

Participants will be randomly put into one of two groups: one group will use the app, while the other will continue to get usual care without the app. Participants will have access to the app for 12 months. They will be asked about their experience, how they are feeling, and their health status at several timepoints.

At the end of the study, the two groups will be compared to see how active and engaged participants are in their treatment and see how this changes over 12 months. The study team will also examine how participants are feeling emotionally and their overall quality of life. Health service utilization data and chart review will be used to examine how patients used health services over the course of their treatment. Qualitative interviews will be conducted for some patients about their treatment and experience on the app, using photos that they submit throughout the study.

調査の概要

状態

まだ募集していません

条件

介入・治療

研究の種類

介入

入学 (推定)

200

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Tulin Cil
  • 電話番号:3984 416-946-4507
  • メール:tulin.cil@uhn.ca

研究連絡先のバックアップ

研究場所

    • Ontario
      • Toronto、Ontario、カナダ、M5G2M9
        • University Health Network
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Females (assigned female at birth)*
  • Diagnosed with primary invasive BC and receiving curative intent treatment
  • Must have neoadjuvant chemotherapy as their first step in treatment
  • Receiving systemic therapy at UHN
  • Age≥18
  • Access to an electronic device with connection to the internet
  • A valid email address
  • Can communicate in English

Exclusion Criteria:

  • Males (assigned male at birth), as BC surgical treatment options and experiences are different
  • Diagnosed with non-operable breast cancer
  • Stage 4/metastatic (whether determined at diagnosis or during surgery)
  • Those with hearing or visual challenges
  • Should not be enrolled in any other UHN study using an e-Health application

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Control

Standard care

実験的:Intervention (App)

App + standard care

The app is a customized version of an eHealth platform that is already in use in other disease sites at UHN. The app has been approved by UHN as a secure communication method. We have customized the app to function within breast cancer care pathways.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Patient Activation Measure 13 (PAM-13)
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 13-item scale measuring self-reported knowledge, skills and confidence for self-management of one's health and healthcare. Items are rated on a 4-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher scores indicate a greater patient activation.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

二次結果の測定

結果測定
メジャーの説明
時間枠
Impact of Events Scale - Revised (IES-R)
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 22-item scale measuring subjective distress as it relates to a specific event, based on intrusion and avoidance. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
Generalized Anxiety Disorder 7 (GAD-7)
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 7-item measure of generalized anxiety disorder based on symptoms. The GAD-7 is scored by adding its seven items (each 0-3), producing a total from 0-21. Higher scores indicate higher anxiety.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire: EORTC QLQ-C30
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 30-item survey assessing of quality of life in cancer patients. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated. Raw item averages are transformed into a 0-100 scale, where higher scores indicate better functioning (for function/global scales) or worse symptoms (for symptom scales).

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire Information Module (EORTC-INFO25)
時間枠:9 months post-baseline

A 25-item survey to measure the amount of medical information received throughout treatment. This scale uses a 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale indicate higher satisfaction with provided treatment information.

9 months post-baseline
European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42)
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 42-item survey assessing quality of life specifically for breast cancer patients.

The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. A high score for functional scale indicate a high/healthy level of functioning while a high score for single item indicate a high level of symptomatology/problems.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
Health Education Impact Questionnaire (heiQ)
時間枠:Baseline 9 months post-baseline

A 40-item scale measuring the intended outcomes of health education and self-management programs. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome.

Baseline 9 months post-baseline
Clinical Evaluation Questionnaire -INS (CEQ-INS)
時間枠:9 months post-baseline

A 19-item scale evaluation of patient's experience of cancer care in terms of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team.

9 months post-baseline
Health Service Outcomes - Wait Times
時間枠:Until 15 months post-baseline

The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals.

Until 15 months post-baseline
Health Service Outcomes - Ambulatory Clinical Activity
時間枠:Until 15 months post-baseline

Ambulatory clinical activity will be collected from the National Ambulatory Care Reporting System (NACRS).

Until 15 months post-baseline
Health Service Outcomes - Discharge Information
時間枠:Until 15 months post-baseline

Discharge information will be collected from the Discharge Abstracting Database (DAD) and used to understand discharge and patient recovery.

Until 15 months post-baseline

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年10月1日

研究の完了 (推定)

2028年10月1日

試験登録日

最初に提出

2026年10月28日

QC基準を満たした最初の提出物

2026年11月15日

最初の投稿 (実際)

2026年11月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月15日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 24-5369

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。